If Sanofi Pasteur, the French drug manufacturing firm will be able to secure a Certificate of Product Registration from the Food and Drug administration, then the controversial anti-dengue vaccine that allegedly killed number of vaccinated children will probably be sold again to the public.
Subject to the decision of the department of Health prior to its meeting with the FDA today to grant Sanofi Pasteur its CPR.
Last October, Sanofi also reported that the European Medicine Agency committee for Medicinal Products for Human Use (CHMP) had approve the use of the said vaccine.
DoH discontinued the use of the vaccine and will never again use Dengvaxia Vaccine for its immunization program an official from the DoH said.
On December 2015, former President Benigno Aquino III met with the officials of Sanofi Pasteur in Paris, making the Philippines the first Asian country to approve the commercial sale of the Dengvaxia vaccineh
In April 2016, the Department of Health (DOH), launched the dengue vaccination campaign in CALABARZON, Central Luzon, and the National Capital Region. Around 700,000 received at least one dose of the vaccine.
On January 2018, around 725 children had been hospitalized due to the adverse effects of the anti-dengue vaccine 400 children who received Dengvaxia vaccine tested positive of dengue.
Last November, reports from the Public Attorney’s Office (PAO) forensic experts said that there are already 102 recipients whose cadavers have undergone forensic examination. Cause of death is the common pattern of symptoms and relatively same gross forensic findings.
The Philippine government paid P3.5-billion for the vaccine.